Covance
3Q Revenues: $415 mlllion (+16%)
3Q Earnings: $45 million (+17%)
YTD Revenues: $1.2 billion (+14%)
YTD Earnings: $125 million (+17%)
Comments: Early development results were up 19% to $200 million, while late-stage services rose 13% to $197 million. During the quarter, the company opened four new facilities: a preclinical ABSL-2 vaccine facility in North America, a preclinical facility expansion in Europe, and two sites in Aisa, a central laboratory and a nutritional chemistry laboratory.
Magazine
